AU2018236286B2 - Forms and compositions of a MK2 inhibitor - Google Patents

Forms and compositions of a MK2 inhibitor Download PDF

Info

Publication number
AU2018236286B2
AU2018236286B2 AU2018236286A AU2018236286A AU2018236286B2 AU 2018236286 B2 AU2018236286 B2 AU 2018236286B2 AU 2018236286 A AU2018236286 A AU 2018236286A AU 2018236286 A AU2018236286 A AU 2018236286A AU 2018236286 B2 AU2018236286 B2 AU 2018236286B2
Authority
AU
Australia
Prior art keywords
compound
acid
disease
complex
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018236286A
Other languages
English (en)
Other versions
AU2018236286A1 (en
Inventor
Jianxin HAN
Lianfeng Huang
Uday Jain
Ying Li
John MALONA
Kevin MOLTER
Chittari Pabba
Alexander L. Ruchelman
Jean Xu
Daozhong Zou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2018236286A1 publication Critical patent/AU2018236286A1/en
Application granted granted Critical
Publication of AU2018236286B2 publication Critical patent/AU2018236286B2/en
Assigned to BRISTOL-MYERS SQUIBB COMPANY reassignment BRISTOL-MYERS SQUIBB COMPANY Request for Assignment Assignors: CELGENE CAR LLC
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Cosmetics (AREA)
AU2018236286A 2017-03-16 2018-03-15 Forms and compositions of a MK2 inhibitor Ceased AU2018236286B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472015P 2017-03-16 2017-03-16
US62/472,015 2017-03-16
PCT/US2018/022543 WO2018170199A1 (en) 2017-03-16 2018-03-15 Forms and compositions of a mk2 inhibitor

Publications (2)

Publication Number Publication Date
AU2018236286A1 AU2018236286A1 (en) 2019-09-19
AU2018236286B2 true AU2018236286B2 (en) 2022-02-17

Family

ID=63522534

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018236286A Ceased AU2018236286B2 (en) 2017-03-16 2018-03-15 Forms and compositions of a MK2 inhibitor

Country Status (8)

Country Link
US (2) US10882867B2 (enExample)
EP (1) EP3595658A4 (enExample)
JP (2) JP2020514360A (enExample)
CN (1) CN110678178B (enExample)
AU (1) AU2018236286B2 (enExample)
CA (1) CA3054823A1 (enExample)
MX (1) MX393600B (enExample)
WO (1) WO2018170199A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201902326XA (en) 2014-09-17 2019-04-29 Celgene Car Llc Mk2 inhibitors and uses thereof
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
CA3054826A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
CN110678178B (zh) 2017-03-16 2023-10-03 百时美施贵宝公司 Mk2抑制剂的形式和组合物
JP2020514361A (ja) * 2017-03-16 2020-05-21 セルジーン シーエーアール エルエルシー ９，１０，１１，１２−テトラヒドロ−８ｈ−［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２−ｆ］キノリン−８−オン化合物およびその使用
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
WO2020236636A1 (en) * 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
EP4284805A1 (en) 2021-02-01 2023-12-06 Celgene Corporation Mk2 inhibitors, the synthesis thereof, and intermediates thereto
AU2023207395A1 (en) 2022-01-14 2024-07-11 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Pyridine-containing polycyclic derivative, and preparation method therefor and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044463A2 (en) * 2014-09-17 2016-03-24 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038705A1 (en) * 1996-04-12 1997-10-23 Bristol-Myers Squibb Company N-formyl hydroxylamine containing compounds useful as ace inhibitors and/or nep inhibitors
AU2003301226A1 (en) 2002-12-20 2004-07-22 Pharmacia Corp Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
US7790712B2 (en) * 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
CN101360750A (zh) * 2005-11-23 2009-02-04 英特芒尼公司 应激活化蛋白激酶系统的调节方法
CN101687869A (zh) 2007-07-16 2010-03-31 诺瓦提斯公司 作为mk2抑制剂的四环内酰胺衍生物
US9126978B2 (en) * 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
CN102464639A (zh) * 2010-11-16 2012-05-23 北京京卫信康医药科技发展有限公司 麦考酚酸钠的新晶型及其制备方法
SG194216A1 (en) * 2011-04-21 2013-11-29 Origenis Gmbh Heterocyclic compounds as kinase inhibitors
EP2872144A4 (en) 2012-07-11 2015-12-02 Nimbus Iris Inc IRAQ INHIBITOR AND USES THEREOF
KR20150133172A (ko) * 2013-03-15 2015-11-27 셀진 아빌로믹스 리서치, 인코포레이티드 Mk2 억제제 및 이의 용도
WO2014210319A2 (en) * 2013-06-26 2014-12-31 The Trustees Of Columbia University In The City Of New York Inhibitors of plasmodium falciparum equilibrative nucleoside transporter type 1 as anti-parasitic compounds
WO2016032882A1 (en) * 2014-08-25 2016-03-03 Stc.Unm Inhibition of mk2 in the treatment of cancer
MX2017008994A (es) 2015-01-08 2018-09-18 Moerae Matrix Inc Formulacion de peptidos inhibidores mk2.
JP2020511468A (ja) 2017-03-16 2020-04-16 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の重水素化アナログおよびその使用
JP2020514361A (ja) 2017-03-16 2020-05-21 セルジーン シーエーアール エルエルシー ９，１０，１１，１２−テトラヒドロ−８ｈ−［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２−ｆ］キノリン−８−オン化合物およびその使用
CN110678178B (zh) 2017-03-16 2023-10-03 百时美施贵宝公司 Mk2抑制剂的形式和组合物
CA3054826A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
US11124525B2 (en) 2017-03-16 2021-09-21 Celgene Car Llc Heteroaryl compounds useful as MK2 inhibitors
WO2020236636A1 (en) 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
KR20230044446A (ko) 2020-07-24 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 급성 호흡기 장애의 치료 방법
EP4284805A1 (en) 2021-02-01 2023-12-06 Celgene Corporation Mk2 inhibitors, the synthesis thereof, and intermediates thereto

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044463A2 (en) * 2014-09-17 2016-03-24 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof

Also Published As

Publication number Publication date
US11629153B2 (en) 2023-04-18
EP3595658A4 (en) 2020-11-25
JP2023017840A (ja) 2023-02-07
US20200148701A1 (en) 2020-05-14
EP3595658A1 (en) 2020-01-22
US10882867B2 (en) 2021-01-05
WO2018170199A1 (en) 2018-09-20
US20210198276A1 (en) 2021-07-01
AU2018236286A1 (en) 2019-09-19
JP2020514360A (ja) 2020-05-21
MX393600B (es) 2025-03-24
CN110678178A (zh) 2020-01-10
CA3054823A1 (en) 2018-09-20
MX2019010643A (es) 2019-10-17
CN110678178B (zh) 2023-10-03

Similar Documents

Publication Publication Date Title
AU2018236286B2 (en) Forms and compositions of a MK2 inhibitor
JP2023051962A (ja) ９，１０，１１，１２－テトラヒドロ－８ｈ－［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２－ｆ］キノリン－８－オン化合物およびその使用
AU2018236290A1 (en) MK2 inhibitors, synthesis thereof, and intermediates thereto
JP2025538371A (ja) 含窒素複素環系化合物の薬用可能な塩、結晶型及び調製方法
TWI771280B (zh) 經取代之5,6-二氫-6-苯基苯并[f]異喹啉-2-胺化合物之固體形式
KR102849420B1 (ko) Jak 억제 화합물의 지나포에이트염
TW202337447A (zh) 含氮并環類衍生物抑制劑的酸式鹽或晶型及其製備方法和應用
EP4134369B1 (en) Solid forms of tetrahydropyranyl amino-pyrrolopyrimidinone compounds
JP2023541140A (ja) Ｂｔｋを分解するための化合物の塩、その結晶形及び医薬品におけるその使用
US11261182B2 (en) Crystal of pyrido[3,4-d]pyrimidine derivative or solvate thereof
CN120917029A (zh) 结晶形式
US10544137B2 (en) PI3K inhibitor, and pharmaceutically acceptable salt, polycrystalline form, and application thereof
CN118251400A (zh) Axl激酶抑制剂的盐、其制备方法和用途
JP2024520920A (ja) イミダゾリジノン類化合物の多形体、調製方法及びその使用
US11999724B2 (en) Method for producing diarylpyridine derivatives
WO2019057121A1 (zh) 一种异喹啉磺酰衍生物的晶型及其制备方法
WO2025217647A1 (en) Stat6 degraders and uses thereof
WO2025242167A1 (zh) Pkmyt1抑制剂的多晶型、其制备方法及其应用
WO2025236004A1 (en) Stat6 inhibitors and uses thereof
HK40062038B (zh) 呋喃并咪唑并吡啶类化合物的合成方法、多晶型物、及盐的多晶型物
EA044028B1 (ru) Ксинафоатная соль соединения, ингибирующего jak
BR112019009448B1 (pt) Cristal de um composto, seu uso e composição farmacêutica

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ HAN, JIANXIN; HUANG, LIANFENG; JAIN, UDAY; LI, YING; MALONA, JOHN; MOLTER, KEVIN; PABBA, CHITTARI; RUCHELMAN, ALEXANDER L.; XU, JEAN AND ZOU, DAOZHONG

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: BRISTOL-MYERS SQUIBB COMPANY

Free format text: FORMER OWNER(S): CELGENE CAR LLC

MK14 Patent ceased section 143(a) (annual fees not paid) or expired